Bioscreening Technology;
Faculty of Biological Sciences;
Institute of Molecular and Cellular Biology;
University of Leeds;
Leeds;
UK;
Scleroderma Research Centre;
Leeds Institute of Molecular medicine;
St James’s University Hospital;
Leeds;
UK;
Section of Experimental Therapeutics;
Leeds Institute of Molecular medicine;
St James’s University Hospital;
Leeds;
UK;
Section of Experimental Therapeutics;
Leeds Institute of Molecular medicine;
St James’s University Hospital;
Leeds;
UK Discovery Technology;
Avacta Group plc;
Wetherby;
UK;
Fibrosis; Biomarker; Peptide; Aptamer; Systemic; Sclerosis; Proof; of; Concept;